Results 31 to 40 of about 1,504,385 (337)

A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]

, 2014
Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie, Hamers, Claude, Hudelet, Pascal, Nunes, Sandro Filipe, Palmarini, Massimo, Ratinier, Maxime, Shaw, Andrew   +6 more
core   +2 more sources

Protection efficacy of Argentinian isolates of Mycobacterium avium subsp. paratuberculosis with different genotypes and virulence in a murine model [PDF]

, 2018
Paratuberculosis is a chronic disease caused by Mycobacterium avium subsp. paratuberculosis (Map). The disease causes economic losses and, therefore, it is imperative to follow proper control strategies, which should include an effective vaccine. Several
Alvarado Pinedo, María Fiorella, Colombatti Olivieri, María Alejandra, Delgado, Fernando Oscar, Gravisaco, Maria Jose Federica, Mon, Maria Laura, Moyano, Roberto Damian, Romano, Maria Isabel, Santangelo, María de la Paz, Travería, Gabriel Eduardo   +8 more
core   +1 more source

Envelope Determinants of Equine Lentiviral Vaccine Protection [PDF]

, 2013
Lentiviral envelope (Env) antigenic variation and associated immune evasion present major obstacles to vaccine development. The concept that Env is a critical determinant for vaccine efficacy is well accepted, however defined correlates of protection ...
A Kumar, A Kumar, AJ Mcmichael, AT Das, B Berkhout, BA Sponseller, BF Haynes, C Leroux, C Leroux, C Leroux, CH Grund, Charles J. Issel, CJ Issel, Corin Ezzelarab, D Shental-Bechor, David Horohov, DC Montefiori, DL Lichtenstein, DL Lichtenstein, EW Uhl, F Li, F Li, F Li, J Mills, JB Whitney, JK Craigo, JK Craigo, JK Craigo, JK Craigo, JK Craigo, JK Craigo, JK Craigo, JK Craigo, JM Ball, Jodi K. Craigo, K Abel, KA Hussain, L Coggins, L Howe, L Howe, Liu Chong, M Busch, MJ Papandreou, ML Raabe, MR Raabe, MR Reynolds, N Almond, PM Rwambo, PM Rwambo, R Hofmann-Lehmann, RC Montelaro, RF Cook, RM Ruprecht, Ronald C. Montelaro, RP Johnson, RP Johnson, RP Johnson, RR Amara, S Hambleton, SA Hammond, SA Hammond, SA Hammond, Sheila J. Cook, SL Payne, SM Blower, SM Harrold, SZ Wang, TL Tagmyer, TL Tagmyer, TW Baba, TW Baba, WC Koff, WM Bogers, Y Kono, YH Zheng, YH Zheng, Zhiping Ye   +76 more
core   +3 more sources

Influenza and memory T cells : how to awake the force [PDF]

, 2016
Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals.
Glezen, Hartshorn, Hufford, Jin, Jordan, Luo, Mosmann, Razvi, Topham, Topham, Topham, Von Andrian, Wijburg   +12 more
core   +3 more sources

Vaccines against toxoplasma gondii : challenges and opportunities [PDF]

, 2009
Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects.
Aliberti J, Angus CW, Aosai F, Aosai F, Awan KJ, Beghetto E, Bommireddy R, Bonenfant C, Boyle JP, Brinkmann V, Buxton D, Bülow R, Caetano BC, Conacher M, Cong H, Cong H, Constant SL, Couper KN, Craig W Roberts, Cui YL, Cuppari AF, Curtsinger JM, Curtsinger JM, Cutchins EC, Darcy F, Dautu G, Debard N, Debierre-Grockiego F, DeGregorio E, Denkers EY, Desolme B, Duquesne V, Echeverria PC, Elisabeth Förster-Waldl, Erik Jongert, Escajadillo A, Eskild Petersen, Fachado A, Fachado A, Flori P, Fox B, Frenkel JK, Garcia JL, Garcia JL, Gatkowska J, Gazzinelli R, Gazzinelli RT, Golkar M, Hakim FT, Igarashi M, Innes EA, Ishii K, Ishii KJ, Ismael AB, Ismael AB, Johnson LL, Jongert E, Jongert E, Jongert E, Kasper LH, Khan IA, Kijlstra A, Kodjikian L, Krahenbuhl JL, Kringel H, Letscher-Bru V, Letscher-Bru V, Leyva R, Lindsay DS, Liu Q, Lourenco EV, Lourenço EV, Martin V, McLeod R, Mishima M, Mishima M, Mohamed RM, Mévélec MN, Mévélec MN, Nicola Gargano, Nielsen HV, Nielsen HV, Petersen E, Petrovsky N, Pettersen EK, Pfefferkorn ER, Qu D, Reikvam A, Roque-Resendiz JL, Sabin AB, Sayles PC, Schaap D, Scorza T, Siachoque H, Sibley LD, Silveira C, Stanley AC, Stockinger B, Supply P, Taneja V, Vandepapelierea P, Velge-Roussel F, Velge-Roussel F, Vercammen M, Vogel N, Vyas JM, Waldeland H, Wang H, Wilkins MF, Williams MA, Xue M, Xue M, Yang CD, Yarovinsky F, Zenner L, Zhang G, Zhang J, Zimmermann S   +117 more
core   +3 more sources

Identification of an essential virulence gene of cyprinid herpesvirus 3 [PDF]

, 2017
The genus Cyprinivirus consists of a growing list of phylogenetically related viruses, some of which cause severe economic losses to the aquaculture industry. The archetypal member, cyprinid herpesvirus 3 (CyHV-3) causes mass mortalities worldwide in koi
Boutier, Maxime, Davison, Andrew J., Gao, Yuan, Suárez, Nicolás, Vancsok, Catherine, Vanderplasschen, Alain   +5 more
core   +2 more sources

Post vaccinal temporary sensorineural hearing loss [PDF]

, 2018
In our systematic research we identified four studies concerning the onset of neurological adverse events following vaccination and two excluding this association.
De Cesare, Donato Pompeo, De Marco, Federica, Di Folco, Francesco, Di Luca, Natale Mario, Massoni, Francesco, Ricci, Serafino, Sacco, Carmina, Tomei, Francesco, Tomei, Gianfranco   +8 more
core   +1 more source

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. [PDF]

, 2015
The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized
Anis E, Davis DC, Edward PK Parker, Ghendon YZ, Glezen WP, Glezen WP, Herremans MM, Herremans TM, Hovi T, Kathleen M O’Reilly, Margarita Pons-Salort, Marine WM, Natalie A Molodecky, Nicholas C Grassly, Ogra PL, Wehrle PF, WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines   +16 more
core   +3 more sources

Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines

Vaccines, 2020
Safety, efficacy, and cost-effectiveness are paramount to vaccine development. Following the isolation of rotavirus particles in 1969 and its evidence as an aetiology of severe dehydrating diarrhoea in infants and young children worldwide, the quest to ...
Olufemi S. Folorunso, O. Sebolai
semanticscholar   +1 more source

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR, Elena Stylianou, Helen McShane, Matthew J. Paul, Rajko Reljic, Resende Co T, Rodriguez A, Uranga S, Wong EA   +8 more
core   +1 more source